**Supplemental TABLE 1.** Titration, treatment period, and taper dosing

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Lead-study** | |  | **Extension** | | |
|  | **Titration**  **(Days 1–7)**  **Dose, mg** | **Treatment**  **(Weeks 1–8)**  **Dose, mg** | **Transition\***  **(Week 9)**  **Dose, mg** | **Starting Dose, mg** | **OL Dose, mg** | **Taper Dose, mg** |
| **Study 1030** |  |  |  |  |  |  |
| Placebo | placebo | placebo | — | 25 | 20, 25, 35, or 50 | Ending dose 20 or 25 mg:  Weeks 1–2: 10 mg  Ending dose 35 mg:  Week 1: 20 mg  Week 2: 10 mg  Ending dose 50 mg:  Week 1: 25 mg  Week 2: 10 mg |
| Desvenlafaxine Low Exposure Group† |  |  |  |
| ≥20 kg and <35 kg | 10 | 20 | — |
| ≥35 kg and <70 kg | 10 | 25 | — |
| ≥70 kg | 20 | 35 | — |
| Desvenlafaxine High Exposure Group† |  |  |  |
| ≥20 and <35 | 10 | 25 | — |
| ≥35 and <70 | 10 | 35 | — |
| ≥70 | 20 | 50 | — |
| **Study 1031** |  |  |  |  |  |  |
| Placebo | placebo | placebo | placebo | 25 | 20, 25, 35, or 50 | Ending dose 20 or 25 mg:  Weeks 1–2: 10 mg  Ending dose 35 mg:  Week 1: 20 mg  Week 2: 10 mg  Ending dose 50 mg:  Week 1: 25 mg  Week 2: 10 mg |
| Desvenlafaxine† |  |  |  |
| ≥20 kg and <35 kg | 10 | 25 | 25 |
| ≥35 kg and <70 kg | 10 | 35 | 25 |
| ≥70 kg | 20 | 50 | 25 |
| Fluoxetine | 10 | 20 | placebo |

\*Included in between lead-in study and Study 1031 only.

†Dosing based on lead-in study baseline body weight